Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Clinical trial NCT07562152 · RECRUITING

Trial details

NCT number: NCT07562152
Sponsor: Immuneering Corporation
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Pancreatic Cancer Pancreatic Cancer Metastatic PDAC PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma Pancreatic Adenocarcinoma Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma

Start date: 2026-06-05
Primary completion: 2028-06-01
Enrollment: 510

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.